Bavarian Nordic
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bavarian Nordic sits in the top decile of US sponsors by registered trial count (#429 of 15,742 sponsors by registered trial count).
Bavarian Nordic: 41 sponsored US clinical trials, 2 recruiting.
Bavarian Nordic sponsors 41 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 36 completed. 14 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chikungunya Virus Infection, with 2 trials.
Top-decile sponsor footprint
Bavarian Nordic ranks in the top decile of sponsors by registered trial count (#429 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
36 of 37 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
41 total, page 1 of 1
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
NCT07199569
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
NCT06007183
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
NCT05329220
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
NCT05349617
MVA-BN-RSV Vaccine Trial
NCT05238025
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
NCT05065983
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
NCT05072080
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
NCT04246671
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer
NCT04134312
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
NCT03992872
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
NCT04131595
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
NCT03699124
BN Brachyury and Radiation in Chordoma
NCT03595228
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT03628716
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
NCT03483961
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)
NCT03349983
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
NCT03220737
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
NCT02840994
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
NCT02873286
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
NCT02391909
Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine
NCT02419391
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
NCT02100631
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
NCT02094586
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
NCT02038881
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
NCT01895855
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
NCT01668537
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
NCT01144637
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
NCT01585181
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
NCT01322490
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
NCT01152398
Special Access Program IMVAMUNE®
NCT03472014
A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects
NCT00857493
Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects
NCT00623259
A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer
NCT00629057
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
NCT00485277
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
NCT00316602
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
NCT00316589
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
NCT00189904
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
NCT00078585
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 14 |
| Phase 3 | 12 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Bavarian Nordic pipeline
2 recruiting of 41 indexed (5% open); 36 completed (88%).
Phase mix: 14 late (III/IV) vs 26 early (I/II) (early-phase heavy).
Top condition: Chikungunya Virus Infection (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bavarian Nordic: open-pipeline peers nationwide
Peers matched on 41 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Bavarian Nordic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 41 trials (± recruiting share)
- Friends Research Institute · 41 trials · 12% recruiting
- Scripps Translational Science Institute · 41 trials · 20% recruiting
- Solventum US · 41 trials · 5% recruiting
- United States Naval Medical Center, San Diego · 41 trials · 15% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Christiana Care Health Services · 5% recruiting · 82 trials
- Ferring Pharmaceuticals · 5% recruiting · 83 trials
- Amphastar Pharmaceuticals · 5% recruiting · 21 trials
- Cook County Health · 5% recruiting · 21 trials
Related
What to do with this Bavarian Nordic page
41 registered trials is a research-attention snapshot, not an endorsement of Bavarian Nordic or any single study.
- 2 of Bavarian Nordic's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chikungunya Virus Infection is the condition Bavarian Nordic studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chikungunya Virus Infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bavarian Nordic pipeline card: 41 registered trials from official public datasets.Report a data error.